ChemDiv launches pre-commercial translational R&D program
ChemDiv and the German Center for Neurodegenerative Diseases (DZNE) have launched a pre-commercial translational R&D program with support from Torrey Pines Investment.
Archives for January 8, 2018
Pfizer pays Arvinas $830m to discover drugs that target mis-folded proteins
Pfizer Inc has paid Arvinas Llc $830m (€693m) to develop small molecule drug candidates that treat diseases caused by mis-folded proteins.
Sekisui XenoTech hires in record numbers, expects 10% growth
Sekisui XenoTech hired in record numbers in 2017 as it anticipates 10% or higher growth over the next couple of years fueled by demand for drug-drug interaction studies.
McKesson: RxCrossroads purchase to support pharma’s expanding commercialization needs
McKesson Corporation has completed its acquisition of RxCrossroads to support customer needs beyond channel distribution as the industry faces increasing challenges.
Aslan to make Array's small molecule cancer drug varlitinib under new licensing deal
Aslan Pharmaceuticals Pte Ltd has licensed manufacturing and sales rights to Array BioPharma’s candidate small molecule pan-HER inhibitor varlitinib.